Accepted Manuscript © The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. Evaluation of Vaccine Safety After the First Public Sector Introduction of Typhoid Conjugate Vaccine—Navi Mumbai, India, 2018 Ashley T. Longley 1,2 , Kashmira Date 2 , Stephen P. Luby 3 , Pankaj Bhatnagar 4 , Adwoa D. Bentsi-Enchill 5 , Vineet Goyal 4 , Rahul Shimpi 4 , Arun Katkar 4 , Vijay Yewale 6 , Niniya Jayaprasad 4 , Lily Horng 3 , Abhishek Kunwar 4 , Pauline Harvey 4 , Pradeep Haldar 7 , Shanta Dutta 8 , Jane Gidudu 2 1. National Foundation for the Centers for Disease Control and Prevention, Atlanta, Georgia, USA 2. Global Immunization Division, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA 3. Infectious Diseases and Geographic Medicine, Stanford University, Stanford, California, USA 4. World Health Organization-Country Office for India, National Public Health Surveillance Project, New Delhi, India 5. Department of Immunization, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland 6. Dr. Yewale Multi Specialty Hospital for Children, Navi Mumbai, India 7. Ministry of Health and Family Welfare, Government of India, New Delhi, India 8. National Institute of Cholera and Enteric Diseases, Indian Council of Medical Research, New Delhi, India Corresponding author: Ashley T. Longley Global Immunization Division Center for Global Health Centers for Disease Control and Prevention (CDC) 1600 Clifton Rd NE, Atlanta, GA, 30329 United States of America Alongley@cdc.gov Summary: Using data from passive surveillance, telephone interviews, and active surveillance for adverse events of special interest, no safety signals were identified from the first public sector introduction of Typbar-TCV among children 9 months–14 years old in Navi Mumbai, India. Downloaded from https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab059/6121264 by guest on 26 February 2021